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Malignant melanoma is the most common malignant tumour of the oral cavity in the 
dog, with high rate of metastatic dissemination to the regional lymph nodes and distant 
organs. There is significant overlap in regards of biologic behaviour, histological 
appearance and genomic alterations between canine and human OMMs. Therefore, 
the dog is considered a good preclinical model for this deadly tumour.  
In the first part of this study we aimed to identify genes that are involved in the 
metastatic dissemination of canine OMMs by microarray mRNA profiling of 4 pairs of 
primary tumours and their lymph nodal metastases. These genes could represent a 
future target for the control and hopefully treatment of the metastatic disease. We 
pointed out the presence of several genes displaying different expression between the 
primary and the metastatic tumour. In particular, Rac1 seems to play a key role in the 
dissemination of melanoma cells to the lymph node, most likely due to its regulatory 
activity of cell motility. 
In the second part of the study we assessed the potential improvement of detection of 
lymphatic invasion in canine primary OMMs by using immunohistochemistry for Prox-1, 
as the detection of lymphatic invasion in a primary tumour is generally considered an 
unfavourable prognostic factor for several cancers, including human and canine 
OMMs. We also tried to prove direct correlation between the presence of lymphatic 
invasion in the primary tumour and regional lymph node metastasis. Our results 
showed that Prox-1 IHC is not able to enhance detection of lymphatic invasion in the 
primary site and that the sensitivity of detection of lymphatic invasion in predicting 
lymph nodal metastasis is low (46.7%), despite high specificity (97%). Finally, we 
pointed out the presence of interobserver variability in detecting lymphatic invasion in 



































Origin and functions of melanocytes: 
In vertebrates, melanocytic stem cells originate from the neural crest, emigrate 
dorsolaterally from the neural tube and reach the skin and mucous membranes during 
embryonal development. In the epidermis these stem cells reside in the bulge region of 
the hair follicle although the specific niche in which they reside in the oral mucosa is 
still unknown. As mature melanocytes, they localize in the basal cell layer of the 
epithelium. They are stellate/dendritic cells able to disseminate membrane-bound 
organelles containing melanin (called melanosomes) to the keratinocytes via a network 
of arborizing processes (dendrites). Melanosomes can contain variable amounts of 
eumelanin (imparting a dark colour) and pheomelanin (associated with light skin). 
Different sized melanosomes containing different proportions of eumelanin and 
pheomelanin will determine all the skin/mucosa colour variations 1.   
Melanin synthesis (confined only to melanocytes and retinal pigment cells) is catalysed 
by the enzyme tyrosinase, which converts tyrosine to dihydroxyphenylalanine (DOPA)2. 
The lack of this enzyme results in albinism. Once transported to the keratinocytes, the 
melanin pigment is mainly located over the nucleus forming a supranuclear “cap” in 
order to protect the nuclear DNA from ultraviolet (UV) damage 3. Melanin is not only 
involved in protection against UV damage and imparting colour of skin/mucosal 
surfaces but has several other functions. For example, this pigment is able to provide 
protection against reactive oxygen species (ROS) and free radicals, neutralize bacterial 
enzymes and toxins, and act like a physical barrier against microorganisms. 
Melanocytes have several other functions apart from the synthesis of melanin. Indeed, 
they can be involved in the immune response, mainly as part of the innate immune 
system. They can act like antigen-presenting cells, stimulate T-cell proliferation and 
show phagocytic activity against microorganisms 4. 
 
 
Canine oral malignant melanoma and its role as a model for human disease: 
Incidence: 
Oral cancer accounts for 6% to 7% of canine cancers and malignant melanoma is the 
most common cancer of the oral cavity in dogs (30-40% of oral malignancies)5,6.  
 
Overrepresented breeds are the Cocker Spaniel, Miniature Poodle, Anatolian 
Sheepdog, Gordon Setter, Chow Chow, and Golden Retriever5.  
In human medicine, oral melanomas are considered part of the larger group of mucosal 
melanomas together with melanomas arising from the anogenital regions, oropharynx, 
paranasal sinuses, conjunctiva, parotid glands, oesophagus and the middle ear. They 
represent a rare clinical entity (with a reported incidence of 800 cases per year in the 
United States, in contrast to cutaneous melanomas which are 100x more common)7.  
The incidence reported in the literature points out racial differences with Asians having 
a higher incidence of head and neck mucosal melanomas. Intriguingly, in Japan oral 
mucosal melanoma accounts for 7.5% of all melanomas, in contrast with 1% of all 
melanomas in Caucasians8. 
 
Biologic behaviour: 
In general, canine oral malignant melanomas (OMMs) show more aggressive biologic 
behaviour and shorter median survival time compared to their cutaneous counterpart. 
For dogs treated with surgery alone, the survival rate is less than 35% and metastases 
to regional lymph nodes and distant organs are frequently reported (in up to 74% of 
cases)6,5.  
Human OMMs carry a poor prognosis with a 5-year survival rate of between 25 and 
33% according to the disease stage and location. Head and neck mucosal melanomas 
present with local and/or distant metastasis to the lungs and liver in 50% of cases. 
Lymph node metastatic dissemination is reported in 33% of OMM patients9,7. 
 
Histopathology: 
Several histologic variants of oral melanoma are recognized in the dog: epithelioid, 
spindloid/fibromatous, mixed, and rare types such as whorled/dendritic, balloon cell, 
signet ring cell, clear cell and adenoid/papillary cell6. Amelanotic melanomas represent 
approximately 30% of all canine melanoma cases10. 
Common growth patterns found in human mucosal melanomas are spindled, 
perivascular/peritheliomatous, and solid, with other less-commonly encountered 
 
patterns (pseudopapillary, storiform, and alveolar). Head and neck mucosal 
melanomas are frequently amelanotic (up to 50% of tumours)7.  
 
Somatic mutation profiles: 
Similarities between the somatic profiles of human mucosal melanomas and canine 
OMMs have been identified. Mutations in NRAS have been described in canine OMMs at 
the same hotspots (NRASQ61) as in human cancers. In humans, NRASQ61 is the most 
frequent somatic alteration found in NRAS-mutated melanomas, and in mice models 
this mutation is known to interact with INK4A or β-catenin mutations to promote 
melanoma11. Canine OMMs presents numerous copy number alterations and a 
relatively low single nucleotide variation rate with general non-UV mutation signatures, 
as showed in human mucosal melanomas9. The “chromothripsis like” profile on CFA30 
has been reported in canine OMMs and corresponds to the HSA15 alteration observed 
in human cases. In both species, the MAPK and PI3K pathways are both involved in 
OMM formation and progression9. Interestingly, a recent study has focused on 
presence of recurrently mutated driver genes in different species, comparing mucosal 
human, oral canine and mucosal-like/mucocutaneous equine melanomas. In this study, 
NRAS and TP53 were mutated and PTEN was disrupted by nonsense or frameshift 
mutations in all 3 species12.  
 
Conclusion: 
Dogs represent a relevant preclinical model for human OMMs as naturally occurring 
canine OMMs share several clinical and histopathological characteristics as well as 
somatic mutation profiles with the human disease13. The major benefits of dogs as 
tumour models include the ability to study animals in which cancers develop 
spontaneously and thus are more like reflect the process of human tumourigenesis 
compared to experimentally-induced neoplasms. Furthermore, pets and owners share 
the same environment and they may be exposed to the same carcinogens, which can 
contribute to the tumour development9. 
 
 
The clinical relevance of the regional/draining lymph node metastases: 
Lymphatic vessels are built for transport of fluid and cells away from tissues and 
therefore it may not be surprising that this system represents a major route for 
dissemination of tumour cells. Presence of lymphovascular invasion (LVI) in a primary 
tumour (defined as tumour emboli present within a definite endothelial-lined space) is 
generally considered an unfavourable prognostic factor and has been shown to be an 
independent predictor of worse survival in several human cancers14–17. Presence of LVI 
has also been associated with the decreased overall survival of dogs with melanocytic 
tumours18. However, reported incidence of LVI is disproportionately low compared to 
the incidence of sentinel lymph node positivity on routine histologic evaluation in 
humans19. Several factors may contribute to the low rate of definitive LVI such as 
misinterpretation of stromal retraction artefacts and difficulties with identifying lymphatic 
emboli when tumour cells completely fill the lumen. 
Immunohistochemistry using antibodies specific to the lymphatic endothelium such as 
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) and D2-40 (detecting an 
epitope on podoplanin) has been used in several studies on human cutaneous 
melanomas to assess the potential increased detection of lymphatic invasion compared 
to routine haematoxylin and eosin (H&E) staining. It has been shown that this 
technique is able to enhance the detection of lymphatic invasion up to nine folds 
compared to H&E staining20. 
In veterinary medicine, Sleeckx et al21 tried to assess different specific lymphatic 
endothelial markers in canine FFPE mammary tissue. In this study D2-40 did not show 
immunoreactivity with FFPE canine tissue. Anti-prospero-related homeobox I (Prox-1) 
antibody was considered the best antibody compared to LYVE-1 due to stronger 
positive signal and lower background. However, to our knowledge Prox-1 has been 
only used in canine FFPE tissue to evaluate the intestinal lymphatic vasculature22, to 
differentiate cutaneous angiosarcoma23 and to assess lymphangiogenesis in mammary 
tumours24 but never to enhance detection of LVI. 
After entering the lymphatic system in the primary tumour, neoplastic cells start their 
journey to the regional/sentinel lymph node. The survival and growth of neoplastic cells 
in the metastatic site is strictly related to interactions between the “seed” (cancer cells) 
and “soil” (microenvironment). These interactions have been shown to involve 
chemokine receptors on cancer cells and their ligands in the target organs. 
Interestingly, CXCR3, CXCR4 and CCR7 play a critical role in lymph node metastasis 
 
in several human cancers25. In particular, CCR7 is able to dramatically increase 
metastasis to a draining lymph node when expressed in B16 murine melanoma cells26 
and suppression of CXCR3 expression in B16F10 murine melanoma cells reduces the 
metastatic frequency of these cells to the draining lymph nodes27. 
Lymphatic invasion, and in particular regional/draining lymph node metastases, are 
considered an important prognostic factor in many types of human cancer including 
oral melanomas8, being associated with a poorer prognosis and partially dictating the 
course of treatment28. Additional studies are needed in order to make definitive 
conclusions regarding the clinical significance of lymph node metastasis for canine 
OMMs29. Indeed, only few studies have specifically examined regional lymph node 
metastasis as a prognostic factor, despite local lymph node aspiration with cytology 
being part of the routine staging process for canine OMMs5.  
Despite being recognized as an important prognostic indicator, in human medicine 
there is still an ongoing debate about the role of lymph node metastasis in the 
progression of the disease. Lymph node metastases are indeed considered clinically 
inconsequential by some experts, although others consider them to have the potential 
to seed distant organs. Recently it has been showed by Pereira et al.28 that in a 
melanoma mouse model all animals had lung metastases that originated from both 
lymph node lesions and directly from the primary tumour. Additionally, they revealed 
that lymph node metastases most likely disseminate by invasion of lymph node blood 
vessels rather than through efferent lymphatic vessels. Therefore, although the route of 
cancer dissemination is complex and highly debated, lymph node metastases can be a 
source of cancer cells for distant metastases. Further studies are needed to clarify the 
role of the local dissemination to the regional/draining lymph node in the progression of 
the disease. 
Metastatic dissemination as a sign of malignant transformation: 
Eight alterations of normal cell physiology have been identified in the vast majority of 
malignant neoplastic cells as essential to determine a malignant phenotype: (1) self-
sufficiency in growth signals, (2) insensitivity to anti-growth signals, (3) altered cellular 
metabolism, (4) ability to evade apoptosis, (5) limitless replicative potential, (6) 
sustained angiogenesis, (7) tissue invasion and metastasis, and (8) evasion of the host 
immune response30.  
 
The development of malignant melanocytic neoplasms is attributed to a combination of 
environmental factors and genetic predisposition. Unfortunately, while increased UV 
light exposure is a well-known environmental risk factor for human cutaneous 
melanomas, unknown factors contribute to oral melanoma tumorigenesis31,32. 
Tissue invasion and metastasis are biological hallmarks of malignant tumours as 
benign tumours do not metastasise. Metastasis is defined by the spread of neoplastic 
cells to sites physically discontinuous with the primary tumour. They can reach these 
sites by penetration into blood vessels, lymphatics, and body cavities30. 
Metastatic dissemination appears to be facilitated by pro-metastatic genetic and 
epigenetic changes to the primary tumour genome, and interactions between tumour 
cells and other cells in both the initial and distant microenvironments. Identification of 
pro-metastatic genetic and epigenetic events, and characterization of the pathways 
underpinning the metastatic cascade, is critical to discover molecular targets for the 
prevention and treatment of distant metastases, as this process accounts for the 
largest numbers of deaths from cancer. Metastatic dissemination is complex and 
inefficient: neoplastic cells able to metastasise are rare clones in primary tumours, with 
0.01% or fewer cancer cells entering the circulation and developing into metastases33.  
In malignant melanomas, neoplastic cells are able to disseminate to distant sites most 
likely due to their plastic and highly migratory behaviour that resembles that of neural 
crest cells (NCCs), their embryonic precursors. The malignant neoplastic cells, unlikely 
NCCs, reactivate pro-migratory and pro-invasive pathways resulting in aberrant 
dissemination34.  
Cell migration is a key function of life, establishing and maintaining the proper 
organization in unicellular and multicellular organisms. Large scale migration of 
epithelial sheets during gastrulation or movement of individual cells in the nervous 
system are vital for the development of complex organisms. Later in life, cell migration 
is critical for proper immune response, wound repair, and tissue homeostasis35. This 
process is almost exclusively based on dynamic assembly and disassembly of actin 
filaments. Protrusion of the plasma membrane is mainly formed at the migrating front 
edge of cells and initiate the process of migration36. One mechanism to achieve this 
protrusion is the generation of Arp2/3 complex-containing network, such as the 
lamellopodium. Lamellipodia are formed at the cell periphery by continuous branching 
of the Arp2/3 complex and are frequently associated with mesenchymal migration37. 
 
Comparable structures involving Arp2/3 complex-dependent actin remodelling include 
podosomes and invadopodia38. Podosomes and invadopodia are called 
“invadosomes”. They are adhesion and invasion structures that establish contact with 
the extracellular matrix (EM) and recruit metalloprotease to degrade it39. Podosomes 
reflect the physiological aspect of these structures and are formed in several normal 
cells, including neural crest cells40, whereas invadopodia are found in cancer cells, 
such as melanoma cells41.  
Rho GTPases family is a key regulator factor in both lamellipodia and invasosomes 
formation. In particular, lamellipodia require the activity of the Arp2/3 complex, which is 
activated downstream of the Rac subfamily of small GTPases targeting WAVE 
regulatory complex. On the other hand, invasosomes formation depends on WASP-
mediated activation of the Arp2/3 complex by Cdc4239.  
Recent studies have focused on some of the key players in cytoskeletal organization 
and cell migration, such as RAC1, Fascin1, Lamellipodin and the Scar/WAVE complex, 
to better understand the normal melanoblast behaviour during embryonal migration and 
proliferation42–44 and their potential role in the metastatic process. 
Malignant melanoma genomics: 
Several studies have been conducted in human medicine to try to identify biomarkers 
for melanoma progression and metastasis by use of “omics” platforms such as 
genomics, proteomics, microRNA and exosome analysis.  
For example, the first attempts to identify genes involved in melanoma metastasis 
employed cytogenetic technologies, comparing the karyotypes of tumour cell lines or 
tumour samples that exhibited metastatic or non-metastatic behaviour. More recently, 
several other genomic approaches and functional genomic analyses have been applied 
to achieve these goals45. 
 
Birkeland et al46 have been able to analyse metastatic melanoma deposits from human 
patients by whole-exome-sequencing (WES) and revealed that most mutations are 
truncal events, with driver mutations (e.g. BRAF) almost completely shared between 
lesions, and other mutations (e.g. whole-genome duplication) arising as a late truncal 
event. By WES and whole-genome sequencing it has also been revealed by Furney et 
al that human mucosal melanomas are driven by different mechanisms from their 
cutaneous counterpart, in particular with a lack of UV-associated mutations and more 
copy number and structural variation in mucosal tumours47. Interestingly, BRAF V600E 
mutations are the most frequently identified in human cutaneous melanomas but only 
rarely (<6%) detected in their mucosal counterpart. This points out the need to study 
cutaneous and mucosal melanomas as two different entities, with different somatic 
mutation profiles. Therefore, there is the need to validate therapies specifically for each 
group of melanoma patients (cutaneous versus mucosal) to determine the efficacy of 
specific inhibitors (e.g. BRAF inhibitor). 
The canine OMM genome has been recently the focus of some studies, with gene 
expression profiling proving to be a powerful tool for the identification of genes involved 
in metastasis32. In this study, primary oral malignant melanomas (OMMs) that 
metastasised were characterised by reduced expression of CXCL12 and increased 
expression of APOBEC3A compared to non-metastasising primary OMMs, potentially 
linking these genes to the metastatic process. However, genomic analysis of the 






































• Investigate the molecular basis of canine OMM lymph node metastasis. 
Specific objective: 
Evaluate differences in gene expression between primary OMMs and relative 
regional lymph nodal metastasis by microarray mRNA profiling of 4 pairs of 
primary OMMs and lymph node metastases. 
 
• Test the hypotheses that: 
(a) Immunohistochemical detection of lymphatic endothelial cells is more 
sensitive than haematoxylin and eosin staining at detecting vascular invasion of 
melanoma cells in canine primary OMMs with confirmed lymph node metastasis. 
(b) The presence of endothelial cell immunohistochemistry-detected lymphatic 
invasion is associated with canine OMM regional lymph node metastasis. 
(c) There is strong interobserver agreement in the detection of lymphatic 

















































Gene expression profiling of canine primary OMMs and their 










































Materials and methods: 
Ethics Statements: 
This study (Project number 59-2016) was approved by the Animal Health Trust (AHT) 
Ethics Committee. Informed, written consent was obtained from the owners of dogs 
whose oral melanoma and lymph nodal biopsies were included in this study. A 
melanoma/lymph node biopsy could be withdrawn from the study at any time. Patient 
treatment was unaffected by the study.  
 
Tumour Samples: 
Formalin fixed, paraffin embedded (FFPE) biopsies of canine primary OMMs and 
regional lymph node metastases from 4 dogs were retrieved from diagnostic 
histopathology archives [Pathology Department at the AHT (UK) and Department of 
Pathobiology at the University of Utrecht (Netherlands)]. These tissue biopsies were 
surgically excised from dogs (between 2012 and 2018) for treatment and staging 
purposes, respectively. The confirmed diagnosis of both primary OMMs and metastatic 
OMMs was obtained by microscopic examination of H&E stained sections by a board-
certified pathologist (Di Palma S.), using a light microscope (Nikon Eclipse Ci). 
Histological evidence of lymph node metastasis was defined as the presence of large 
groups of neoplastic cells showing a mass effect on the lymphoid tissue, or the 
presence of small cohesive groups (more than 5 cells per high power field/400x) of 
pleomorphic cells containing melanin pigment. One single representative block was 
selected from each of the primary OMMs and their lymph node metastasis. Each block 
was selected on the basis of an area containing neoplastic cells in the corresponding 
H&E stained section examined. Each area was outlined using a fine-point permanent 
marker using a fine-point permanent (figure 1, left). A piece of Parafilm large enough to 
cover the region of interest was placed on the H&E stained slide. Using a fine-point 
permanent marker, we outlined the entire tissue and the region of interest within the 
tissue on the Parafilm. We transferred the marked Parafilm to the corresponding FFPE 
tissue block, matching the outline with the shape of the OMM tissue in the block. Using 
the tip of a permanent marker, we made shallow but visible indentations along the 
outline of the region of interest (figure 1, right). 
Three tissue cores were extracted from the highlighted area of each FFPE block using 




Figure 1: Left. H&E stained section of a primary canine OMM. The marked area identifies an area of 
interest containing melanoma neoplastic cells seen on microscopic examination. Right. Matched FFPE 
tissue block of tissue section shown in A, with area of interest outlined by multiple indentations. 
    
RNA isolation, purification and quantification: 
Total RNA was isolated from all three tissue cores obtained for each of the four FFPE 
primary OMMs and the four matched lymph node metastases using the RecoverAll 
Total Nucleic Acid Isolation Kit (Appendix 1). This kit has been used as it has been 
optimized for extraction of total nucleic acid from FFPE tissues and it is able to recover 
nucleic acids suitable for next generation sequencing, real-time RT-PCR, PCR, 
mutation screening and microarray analysis. OMM RNA samples were further purified 
(to remove melanin) by spin column filtration (OneStep PCR Inhibitor Removal Kit; 
Zymo Research, Freiburg, Germany) (Appendix 2). Total RNA concentration was 
measured for the selected primary and metastatic OMMs by spectrophotometry 
(NanoDrop 1000 Spectrophotometer, ThermoFisher Scientific, Paisley, UK) (Appendix 
3), followed by fluorometry assay (Quant-iT RiboGreen RNA Assay Kit, ThermoFisher 
Scientific, Paisley, UK) (Appendix 4).  
Quant-iT RiboGreen RNA Assay Kit uses advances fluorophores that become 
fluorescent upon binding to DNA or RNA. Therefore, this technology is more accurate 
compared to UV absorbance readings, as there is no interference from free nucleotides 
or other contaminants. NanoDrop assays have been used to confirm that RNA was 
isolated and these results helped to define how much an aliquot of each RNA sample 
should have been diluted for RiboGreen assays. 
 
Global gene expression profiling: 
RNA amplification, labelling and microarray hybridisation: 
Fragmented, biotinylated single-stranded cDNA was prepared from 29 ng of each of 
the 4 FFPE primary OMMs and matched metastases RNA samples using the 
GeneChip WT Pico Reagent Kit (ThermoFisher Scientific, Paisley, UK) (Appendix 5).  
A mixture of 4 unlabelled synthetic RNAs was added (at the beginning of the 
procedure) to each tumour RNA sample to act as ‘labelling controls’, and a mixture of 4 
labelled bacterial DNAs was added (at the end of the procedure) to each labelled 
tumour cDNA sample to act as hybridisation controls 
Each cDNA was individually hybridised to an array in a Canine Gene 1.1 ST Array Strip 
(ThermoFisher Scientific, Paisley, UK), in a proprietary hybridisation cocktail 
(ThermoFisher Scientific, Paisley, UK). Canine Gene 1.1 ST Array Strip has been used 
as it measures expression, across the entire gene, with higher resolution and accuracy 
than with classical 3`-biased microarray solutions, capturing transcript isoforms that 
may be missed with traditional methods. Array strip washing and streptavidin-
phycoerythrin staining were undertaken by the GeneAtlas System (ThermoFisher 
Scientific, Paisley, UK) Fluidics Station, and array scanning by the GeneAtlas System 
(ThermoFisher Scientific, Paisley, UK)  
 
Microarray data analysis: 
Exon-level probe set expression values were generated by quantile normalisation, log2 
transformation and signal summarisation, performed using the RMA algorithm 
(Summaries of Affymetrix GeneChip probe level data. Irizarry RA et al. Nucleic Acids 
Res. 2003 Feb 15;31(4):e15), implemented within ‘Affymetrix Expression Console 
Software 1.3’ (ThermoFisher Scientific, Paisley, UK). ‘Outlier arrays’ were considered 
to be those that had any single sample quality, labelling quality and hybridisation 
quality metric value ≥2 standard deviations away from the mean of the metric value for 
all the arrays (QC Metrics for Exon and Gene Design Expression Arrays. A summary 




pdf). Outlier arrays were excluded, and processing of the raw probe-level signal 
intensity data repeated to generate both quantile normalised and log2-transformed 
exon and gene-level probe set expression values. Gene-level probe sets (‘Transcript 
clusters’) with ‘crosshyb_type’ = 1 (unique hybridisation target) and ‘category’ = ‘main’ 
annotations (Affymetrix Exon and Gene Array Glossary, 
https://www.affymetrix.com/support/help/exon_glossary/index.affx), and for which at 
least 10% of its exons was ‘present’ (detection above background p-value <0.01; 
Affymetrix Exon Array Background Correction Revision Date: 2005-09-27, Revision 
Version: 1.0, https://assets.thermofisher.com/ 
TFS-Assets/LSG/brochures/exon_background_correction_whitepaper.pdf.) in at least 
≥2 of the primary OMMs and ≥2 of the primary OMM lymph node metastases, were 
considered to be expressed and used for subsequent analyses.  
Similarity between the global expression profiles of primary and lymph node OMMs 
was visualized by hierarchical clustering performed using Cluster48. Transcript clusters 
displaying statistically significant differential expression between primary and OMM 
lymph node metastases were identified by moderated T-test (p-value < 0.05) 
performed using the R Limma package49,50. P-values were adjusted by permutation 
testing51 to compensate for “chance” p-values of 0.05 due to multiple testing. 
Differentially expressed transcription clusters were considered real when they showed 
a fold-change >2 (median OMM lymph node metastasis/median primary OMM 
expression value or median primary OMM/median OMM lymph node metastasis 
expression value). 
 
Functional annotation enrichment analysis: 
The biological processes and pathways overrepresented amongst genes displaying 
different expression between primary OMMs and OMM lymph node metastases were 
identified using DAVID52,53. The functional annotations associated with differentially 
expressed genes were compared with those ascribed to all Transcript clusters 
(‘crosshyb_type’ = 1 and ‘category’ = ‘main’) for which the expression of at least 10% of 
its exons was detected above background in ≥2% of the tumours in the primary OMMs 




Purity and quantity of total RNA isolated from FFPE OMM biopsies:  
Nanodrop assay was used to determine the purity of RNA isolated from the canine 
OMMs. The purity of the RNA samples (as measured by the ratio of the absorbances at 
260nm and 280nm, respectively, and the ratio of the absorbances at 260nm and 
230nm, respectively) are illustrated in figures 2 and 3. 
Both absorbance ratio assays for all samples confirmed the good quality of the isolated 
RNAs. Fluorometry assay with the Quant-iT RiboGreen RNA Assay Kit determined the 
concentration of RNA isolated from the canine primary and metastatic OMMs (figure 4). 
The assay confirmed that the concentration of RNA in each of the OMM RNA samples 
was sufficient for use in the preparation of biotinylated single-stranded cDNA using the 
GeneChip WT Pico Reagent Kit (Appendix 4). The Kit recommends that 2 - 50ng of 
total RNA (in 3 µl, and therefore 0.67-16.67 ng RNA/µl) from FFPE tissue samples is 
employed. The RNA sample with the lowest concentration (sample 4P,9.56 ng RNA/µl) 
dictated that 28.68 ng of each RNA sample was employed to prepare biotinylated 














Figure 2: 260nm/280nm absorbance ratio for each of the primary (P) and metastatic (S) OMMs. 
The red line indicates the ‘idealised’ ratio for pure RNA. This value id indicative of an RNA sample 







Figure 3: 260nm/230nm absorbance ratio for each of the primary (P) and metastatic (S) OMMs. 
The red line indicates the minimal acceptable value d (=1.8). An absorbance ratio below this 
value is considered to have a significant amount of contaminants (e.g. phenol, TRIzol, chaotropic 

































Figure 4: Undiluted concentration (expressed in ng/µl) and total yields (ng in 60 µl) of RNA for 
each of the primary (P) and metastatic (S) OMMs. The value of 60 µl is the volume of Nuclease-



























































Tumours included in differential expression analysis: 
In order to define gene expression patterns acquired by primary OMMs in the process 
of metastatic dissemination to the regional lymph node, we evaluated a cohort of 
canine primary (4) and metastatic (4) OMMs derived from surgically treated dogs. The 
use of matched primary and metastatic tumours was preferred in order to reduce 
sample genetic heterogeneity. 
The microarray data for RNA sample 3S (metastatic tumour) was excluded from the 
analysis because it was an “outlier array” (see Materials and Methods), having an 
‘all_probeset_rle_mean’ quality metric value 2.24 standard deviations away from the 
mean of the metric value of all the arrays. 
The gene-level probe set expression values obtained for 4 primary and 3 metastatic 
OMMs were compared for 9,964 Transcript clusters (category = main; crosshyb_type = 
1). A Transcript cluster was considered to be present if ≥10% of its exons were present 
both in ≥2 primary OMMs and ≥2 metastatic OMMs. 
 
Genes displaying differential expression between primary and metastatic OMMs: 
In total, 501 Transcript Clusters (genes) displayed a statistically difference in 
expression (p-value <0.05) between primary and metastatic OMMs, after permutation 
testing-adjustment. A >2-fold change (median primary/median metastatic expression 
value or median metastatic/median primary expression value) was considered to be 
authentic and more likely to be reproducibly measurable. A cohort of 158 Transcript 
Clusters fulfilling this requirement was identified for further analysis. In total, 141 genes 
(89%) showed higher expression in the metastatic OMMs compared to the primary 






Figure 5: Genes differentially expressed between lymph node metastases and primary OMMs. 
Exon microarray-measured expression of 158 genes in 3 metastatic and 4 primary OMMs. The 
log2-transformed metastatic/primary fold change (y-axis) denotes the difference in gene 









































































Hierarchical clustering analysis assessed the similarity between the expression levels 
of the 158 differentially expressed Transcript Clusters across 4 primary and 3 
metastatic OMMs (figure 6).  
 
Figure 6: Hierarchical clustering analysis of 7 OMMs (4 primary and 3 metastatic) on the basis of 
158 differentially expressed genes with significant p-value and fold-change. P: primary tumour. S: 
metastatic tumour. 
 
Functional annotation enrichment analysis: 
The frequencies of functional annotations assigned to 148 of the 158 Transcription 
Clusters that were differentially expressed between the primary and metastatic OMMs, 
and which had unique Ensembl canine gene IDs,  were compared with those 
associated with all the Transcript Clusters expressed by the OMMs (9,123 of 9,964 
which had associated Ensembl canine gene IDs). Over-represented amongst the 
genes exhibiting differential expression were 4 Gene Ontology Consortium biological 








GO:0045785~positive regulation of cell 
adhesion 
15.187 0.015 APBB1IP, VAV3 CYTH3  
GO:0030036~actin cytoskeleton organization 7.087 0.017 
ELMO1, CORO1A, DOCK2, 
FMNL1     
  
GO:0001768~establishment of T cell polarity 47.249 0.041 CCL19, DOCK2     
GO:0007165~signal transduction 4.588 ≤0.001 
TRAF5, ERBB2IP, SPOCK2, 
CDC42SE2, APBB1IP, LNPEP, 
FYB  
SPARC 
Cell adhesion molecules (CAMs) 7.002 ≤0.0001 
CD226, ICOS, PECAM1, DLA-
DOB, ITGA4       
  
cfa05200: Pathways in cancer 2.741 0.008 
TRAF5, IGF1, PLCB2, 
CDKN1B, JAK1, LEF1 
ADCY2, 
MMP2 
cfa04062: Chemokine signaling pathway 4.951 ≤0.001 
CCR7, PLCB2, ELMO1, CCL19, 
CXCL13, DOCK2, VAV3 
ADCY2 
cfa04670: Leukocyte transendothelial 
migration 
5.001 0.015 PECAM1, VAV3, ITGA4 MMP2 
 
Table 1: Differentially expressed gene-associated enriched functional annotations. GO: Gene Ontology. 











OMM is the most common malignant cancer of the oral cavity in the dog5,6, with 
frequent metastases and low survival rate. The propensity of OMMs to metastasise is 
likely to be associated with changes in gene expression in tumour cells that negotiate 
the metastatic cascade32. However, little is known about genomic alterations that may 
be acquired by canine tumour cells during the “journey” to a lymph node, or a site of 
distant metastasis. Understanding of the basis of this process is fundamental as 
metastatic disease is the most common cause of cancer-associated death both in 
humans and in the canine species. Identification of these alterations could identify 
potential targets for control and treatment of OMM and its metastatic spread. For these 
reasons, we decided to evaluate the differences in gene expression between a cohort 
of canine primary OMMs and relative regional lymph nodal metastasis by microarray 
mRNA profiling. 
As previously discussed, cell motility is fundamental for the metastatic process. 
Acquisition of a migratory phenotype by genomic alteration is putatively accounts for 
the ability of OMM cells to travel along lymphatic vessels and reach the 
regional/draining lymph node.  Functional annotation enrichment analysis of genes 
differentially expressed between primary and metastatic OMMs has highlighted the key 
role of the control of cell motility by showing differential expression of genes involved in 
actin cytoskeleton organization, establishment of T cell polarity and leukocyte 
transendothelial migration.   
 
Cell motility:  
Several of the genes differentially expressed between primary and metastatic OMMs 
that are associated with cell motility are reported to be directly and/or indirectly involved 
in the regulation of the Rac1 pathway. These genes are also frequently correlated with 
highly aggressive tumours subtypes.  In our study most of the genes show an 
increased expression in the metastatic site compared to the primary tumour, with 
subsequent potential higher activation of Rac1. As previously mentioned in the 
introduction, Rac1 represents one of the key players in cytoskeletal organization and 
cell migration.  
 
 
Genes upregulated in canine OMM lymph nodal metastases that are involved in Rac1 
regulation: 
• VAV3 is a member of the VAV gene family. The encoded VAV proteins activate 
pathways leading to actin cytoskeletal rearrangements, mainly acting as a 
guanine nucleotide exchange factor for RhoG, RhoA and Rac1 
(uniprot.org/uniprot/Q9UKW4). Elevated VAV3 expression has been linked to 
prostate cancer progression and post-treatment recurrence54.  
• Dock2 is a member of the CDM family proteins, known to regulate actin 
cytoskeleton by functioning upstream of Rac55. DOCK2 activates RAC and 
regulates actin cytoskeleton through the interaction with ELMO156. Proteins 
encoded by ELMO1 interact with dedicator of cytokinesis proteins to promote 
phagocytosis and cell migration57. Mutation-effected aberrant activation of 
ELMO1 and DOCK2 has been reported in human oesophageal 
adenocarcinoma, a highly-invasive tumour prone to early metastasis58.  
• Coronin1A (encoded by Coro1A gene) seems to be a crucial component of the 
cytoskeleton in highly motile cells, functioning in forming protrusions of the 
plasma membrane involved in cell locomotion (uniprot.org/uniport/P31146). 
Overexpression of Coronin1A induces the translocation to the plasma 
membrane of Rac1 and favours its activation59. 
• Integrin alpha 4 (ITGA4) mediates cell-cell adhesion important in immune 
function (uniprot.org/uniprot/P13612). ITGA4 is also widely expressed in neural 
crest cells, leukocytes, striated and smooth muscle, and neurons, and mediates 
their migration, most likely co-localizing and activating Rac60. Moreover, ITGA4 
expression has been demonstrated in human gastrointestinal stromal tumours 
(GISTs) and high expression has been associated with unfavourable 
prognosis61. 
• Chemokine ligand 19 (CCL19) binds to the chemokine receptor 7 (CCR7) and 
is involved in immunoregulatory and inflammatory processes 
(uniprot.org/uniprot/Q99731). Chemokines are also involved in all stages of 
tumour development due to their ability to induce cytoskeleton rearrangement, 
firm adhesion to endothelial cells and directional migration. For example, CCR7 
expression in non-metastatic melanoma cell line renders it able to migrate to 
the lymph nodes in vivo62 and the level of activated Rac was found to be 
 
significantly increased after CCL19 treatment of human metastatic squamous 
cell carcinoma cell lines63. 
• We also found the end results of Rac1 pathway activation by detecting higher 
PLCB2 expression. Indeed, phospholipase C-β2 (PLCB2) has an important role 
in intracellular transduction of many extracellular signals 
(uniprot.org/uniprot/A3KGF7). Activation of this molecule has been shown to be 
stimulated by Rac1 and other Rho GTPases64. 
• FMNL1 also showed increased expression in the metastatic OMMs, despite its 
inhibitory activity for Rac1. FMNL1 is part of the formin family proteins which are 
key regulators of actin and microtubule cytoskeletal dynamics 
(uniprot.org/uniprot/O95466). FMNL1 mediates the formation of F-actin 
networks and can organize actin filaments into bundles, interacting with Rac1 
and RhoA. FMNL1 silencing has been shown to increase Rac1 activity65. 
• CDKN1B also known as p27Kip1 is a tumour suppressor that negatively 
regulates cell cycle progression (uniprot.org/uniprot/P46527). Selective 
deletion/inactivation of the p27Kip1 gene is rarely found in human malignancies. 
Instead, p27 is often translocated from the nucleus to the cytoplasm and this 
translocation has been demonstrated to dramatically increase both cell motility 
and metastasis in vivo in a low metastatic melanoma cell line66. Moreover, p27 
can directly promote cell invasion by facilitating invadopodia turnover via the 
Rac1/PAK1/Cortactin pathway67. 
• CDC42 Small Effector 2 (CDC42SE2, or SPEC2) is part of the family of Cdc42 
effector proteins (uniprot.org/uniprot/Q9NRR3). Together with SPEC1, SPEC2 
is strongly involved in coordinating and/or mediating Cdc42 signalling activities 
and weakly involved with Rac168. In particular, they inhibit Cdc42-induced c-Jun 
N-terminal kinase (JNK) activation and induce formation of cell surface 






Genes downregulated in canine OMM lymph nodal metastases that are involved in 
Rac1 regulation: 
• Downregulation of SPARC expression is related to the Rac1 pathway. Secreted 
protein acidic and cysteine rich (SPARC) is a matrix-associated protein, usually 
playing a role in bone mineralization, cell-matrix interaction and collagen 
binding (uniprot.org/uniprot/P07214). Its expression has been associated with 
aggressive, mesenchymal-like phenotype in a variety of human cancers, 
including melanoma. In particular its expression in melanoma cells was 
associated with decreased E-cadherin and increased N-cadherin expression 
levels suggesting that this protein may regulate epithelial–mesenchymal 
transition69. There is evidence that SPARC is a permissive factor for Rac1 that 
becomes fully active only when SPARC levels are low; indeed, suppression of 
SPARC expression induces the formation of lamellipodia extension70. 
• Matrix metallopeptidase 2 (MMP2) is able to cleave components of the 
extracellular matrix specifically gelatin type I and collagen types IV, V, VII and X 
(uniprot.org/uniprot/P08253). It has been shown that Membrane Type 1 
Metalloprotease (MT1-MMP), highly expressed in neural crest cells, mediates 
human melanoma cell invasion through the activation of its target MMP2 and 







Figure 7: Rac1 pathway activating and inhibitory factors highlighted by differential gene expression and 
functional annotation enrichment analysis. Genes expressed at a higher level in metastatic OMMs 
compared to primary OMMs are highlighted in green and genes expressed at a lower level in metastatic 
OMMs in red. The arrow at the end of a line indicates activation of the target gene. A vertical bar at the 











Genes downregulated in canine OMM lymph nodal metastases that are apparently 
independent from the Rac1 pathway, but are involved in cell motility: 
• Adenylate cyclase 2 (ADCY2) catalyses the formation of cAMP and mediates 
indirectly changes in gene expression patterns (uniprot.org/uniprot/Q08462). 
ADCY2 was shown to be enriched in the calcium signalling pathway and 
potentially being involved in the metastasis of human prostatic carcinoma72. 
Interestingly, calcium (Ca2+) is a crucial regulator of cell migration, with a stable 
and transient gradient increasing from the front of migrating cells to the rear, 
promoting myosin II contraction73. However, Ca2+ influx has been linked to both 
increased and decreased migration, depending on cell types and stimuli73. 
Therefore, the significance of potential increased Ca2+ influx in our cohort of 
canine metastatic OMMs is unclear. 
• SPOCK2, also known as testican-2, is a gene encoding a protein which binds 
with glycosaminoglycans to form part of the extracellular matrix. It is known 
that secreted SPOCK2 plays a significant role in the development and 
progression of several human cancers, mainly regulating the expression of 
Membrane Type 1 Metalloproteinase (MT1-MMP) and Matrix Metalloproteinase 
2 (MMP2)74. Increased expression of SPOCK2 in the metastatic OMMs may 












The Rac1 pathway and its role in melanoma metastasis: 
Rac1 (Ras-related C3 botulinum toxin substrate 1) is the major ubiquitous isoform of 
Rac expressed in mammalian tissue, as part of the Rho family of small GTPases. This 
isoform controls assembly of the cellular actin cytoskeleton primarily via activation of 
the Scar/Wave complex (uniprot.org/uniprot/P63000). Lamellipodia (see Introduction) 
are actin polymerizations at the leading edge of cells, representing the main force for 
cell migration, and their formation is under the control of Rac1. Indeed, loss of Rac1 in 
tissues and cell cultures leads to the loss of lamellipodia and a general reduction of 
migration speed42. The results of the current study support the hypothesis that 
activation of the Rac1 pathway (downstream effectors and upstream regulators of 
Rac1) facilitates canine OMM cell migration to a regional lymph node.  
Rac1 is implicated in epithelial-mesenchymal transition (EMT), inducing downregulation 
of E-cadherin and upregulation of N-cadherin, vimentin and snail1 in human cancers75. 
Melanocytes do not belong to the epithelial lineage and therefore the term EMT cannot 
be formally attributed to the progression of malignant melanoma. However, 
differentiated melanocytes do express E-cadherin and loss of this protein, which 
represents a hallmark of EMT in epithelial tumours is also evident in late stage 
malignant melanomas, especially in nodal metastases76.   
Rac1 is also involved in the transcriptional modulation of gene expression through 
NFkB, JNK and MAPK activation and later induction of AP-1 transcription factors 
involved in cell proliferation77. Novel activities of Rac1 have been recently described, 
such as regulation of the induction of DNA damage response mechanisms in 
cardiomyocytes78 and involvement in vascular integrity and angiogenesis during blood 
vessel sprouting79. 
Rac1 has been identified as a novel candidate gene harbouring putative somatic 
mutations in human cutaneous melanomas. In particular the P29S hot spot mutation 
likely destabilises Rac1 favouring its active GTP-bound state80. Intriguingly, both 
Rac1p29s mutant melanomas cells and Rac1 wild type melanoma cells reduce their 
proliferation by downregulation of Rac1. These results suggest that Rac1 is a good 
target for therapy in human medicine, because it is active also in RAC1 wild type 
melanomas by other molecular events. Some of these events might be similar to the 
putative Rac1 pathway activation-promoting gene expression changes identified in the 
current study. 
 
Despite the fact that the majority of the Rac1 pathway-associated differentially 
expressed genes were putatively positively regulating the Rac1 pathway, two genes, 
FMNL1 and MMP2, seemed to go against this trend.  
To try to explain this apparent contradiction with activation of the Rac1 pathway and 
therefore of cell motility, we may think about the process of invasion and cell migration 
as a dynamic event, balancing between interaction/degradation of the extracellular 
matrix (by invadopodia) and cell movement (by lamellipodia). Indeed, although Rac1 is 
required for migration, high levels of Rac1 activity can impair migration65. Based on this 
hypothesis, we can speculate that the lymph node environment is most likely to be 
more favourable for a cell with an “exploration and invasion” phenotype rather than with 
an “adhesion and invasion” phenotype. The ability to degrade the extracellular matrix 
and interact with it is probably more important in the primary site, whilst the control of 
cell plasticity/motility seems to play a key role while reaching the lymph node. This 
hypothesis of a favourable “exploration and invasion” phenotype in metastatic 
dissemination is also supported by the higher expression of CDC42SE2 observed in 
the metastatic OMMs. Cdc42 small effector protein 2/SPEC2 inhibits Cdc42-induced 
cell shape changes68. As previously mentioned, Cdc42 is more involved in invadopodia 
rather than lamellipodia formation and lamellipodia are a key feature of the “exploration 
and invasion” phenotype.  
 
Cell interactions: 
A fundamental property of neoplastic cells is the ability to interact with other cells, 
driving/controlling them in order to favour tumour survival and dissemination. Several of 
the genes shown to be upregulated in metastatic OMMs in this study encode surface 
molecules that interact with endothelial cells and inflammatory cells. Elevated 
expression of these genes is potentially associated with a specific phenotype that 
confers a selective advantage. Indeed, neoplastic cells able to interact with both 
lymphatic vessels and the lymph node environment are most likely to be able to survive 




Genes upregulated in canine OMM lymph nodal metastases that are involved in cell-
cell interactions:  
• FYB, also known as the adhesion and degranulation promoting adapter protein, 
positively mediates T cell receptor-dependent as well as integrin-mediated cell 
adhesion (uniprot.org/uniprot/O15117). Overexpression of FYB has been 
correlated with ductal carcinoma in situ progression to intraductal carcinoma 
and breast cancer metastasis in humans81. 
• CD226 encodes a glycoprotein expressed on the surface of NK cells, platelets, 
monocytes and a subset of T cells. This protein mediates cellular adhesion of 
platelets and megakaryocytic cells to vascular endothelial cells (RefSeq, Jan 
2015). A similar interaction with endothelial cells can be hypothesised for 
neoplastic cells expressing this molecule.   
• Platelet/endothelial cell adhesion molecule 1 (PECAM1) is expressed on the 
surface of several cell types including platelets, leukocytes and endothelial 
cells. In one study, a subpopulation of PECAM1+ melanoma cells have been 
identified. These cells were more motile than PECAM1- melanoma cells and 
were able to form vascular-like structures (vasculogenic mimicry)82. 
• APBB1IP (Amyloid Beta Precursor Protein Binding Family B Member 1 
Interacting Protein) is also known as the RIAM (Rap1-GTP-interacting adaptor 
molecule), and appears to be involved in actin cytoskeletal remodelling 
(uniprot.org/uniprot/Q7Z5R6). The RIAM/integrin/talin complex has been shown 
to localise at the tips of growing actin filaments in lamellipodial and filopodial 
protrusions, acting like “sticky fingers” at the leading edge of migrating cells83. 
• Chemokine C-X-C motif ligand 13 (CXCL13) is a chemotactic protein for B cells, 
interacting with the receptor CXCR5 (uniprot.org/uniprot/Q99616). In a study 
focusing on CXCL13 expression in melanocytic cells, CXCL13 was strongly 
expressed in a minor subpopulation of tumour cells in primary melanoma, while 
a greater fraction of cells in the metastatic melanoma tissue expressed this 
protein. In the same study, CXCL13 was not detected in normal human 
epidermal melanocytes in situ therefore suggesting a potential role as both a 
specific biomarker for melanoma and a therapeutic target84. 
 
 
• DLA-DOB is a MHC class II molecule, usually expressed on antigen-presenting 
cells (uniprot.org/uniprot/Q5W418). However, recent studies have shown that 
these molecules are expressed in almost 50% of human melanoma and they 
can increase migration and invasion of melanoma cells85. 
• Lymphoid enhancer-binding factor-1 (LEF1) is usually expressed in lymphoid 
cells. However, in one study, expression of the encoded protein has also been 
demonstrated in human melanoma cell lines and correlated to different 
phenotypes. Interestingly, expression of LEF1 is high in proliferative phenotype 
human melanoma cells in vitro and relatively low in low proliferative/high 
invasive populations. Apparently, the human metastatic phenotype lightly 
reduces the expression of LEF186. These results contrast with that of the 
present study, where LEF1 was found to exhibit a 3-fold higher level of 
expression in the lymph node metastases than in the primary OMMs. 
 
Cancer progression and cell survival: 
As previously mentioned (see Introduction), eight alterations of normal cell physiology 
are essential to determine a malignant phenotype30. In regard to tissue invasion and 
metastasis, the results of the present study suggest that changes in gene expression in 
metastasising OMM cells promote increased cell motility assisting travel within the 
lymphatic system. Metastasising OMM cells also express certain proteins that enhance 
their interactions with other cells and the surrounding environment. In addition, a 
number of the genes shown to be differentially expressed between the primary tumours 
and lymph node metastases may be involved in metastatic spread via increasing cell 








Upregulated genes in canine OMM lymph nodal metastasis involved in cancer 
progression and cell survival: 
• Several studies have focused on TRAF5 (tumour necrosis factor receptor-
associated factor 5) due to its pivotal role in cancer progression. For example, 
upregulation of TRAF5 has been confirmed in human gastric cancer tissue87, 
down-regulated TRAF5 caused significant inhibition of cell proliferation and 
promotion of apoptosis in melanoma cell88 and its tumour-promoting activity has 
been demonstrated for colorectal cancer89. 
• ERBB2 interacting protein (ERBB2IP) binds to the receptor tyrosine-protein 
kinase ERBB-2, mainly in epithelia, regulating its function and localisation and 
leading to uncontrolled cellular proliferation and oncogenesis 
(uniprot.org/uniprot/Q80TH2). ERBB2IP has been reported to contribute to the 
tumorigenesis of human hepatocellular carcinoma90. Moreover, ERBB2 
amplifications and mutations have been reported in human melanomas 
(including the mucosal subtype) and clinical trials assessing response to 
targeted therapy for ERBB2-altered melanomas are currently ongoing91. 
• Insulin-like growth factor 1 (IGF-1) is a hormone similar to insulin but with a 
much higher growth-promoting activity (uniprot.org/uniprot/P05017). IGF-1 has 
been identified as a key driver of cell proliferation, in the development and 
growth of multiple tumours and in the prevention of apoptosis. In particular, 
IGF-1 inhibition has been shown to reduce the stemness features and 
functional characteristics of melanoma-initiating cells92. 
• JAK1 encodes a tyrosine kinase involved in the IFN-alpha/beta/gamma signal 
pathway (uniprot.org/uniprot/P23458). JAK1 is able to activate STAT5, a signal 
transducer and activator of transcription that is frequently activated in human 
patients with cutaneous melanoma metastases93. STAT5 plays a key role in 
malignant transformation of haematological malignancies, breast, prostate and 





Genes downregulated in canine OMM lymph nodal metastases that are involved in 
cancer progression and cell survival: 
• CYTH3 (also called Grp1) is a guanine nucleotide exchange factor that 
facilitates the exchange of GDP for GTP to generate the active form of ADP 
Ribosylation Factor 6 (ARF6). Arf6 has been shown to be essential for the 
activation of Hepatocyte Growth Factor-induced tumour angiogenesis94 (. In this 
study, increased expression of CYTH3 at the primary site is consistent with the 
need for a blood supply to support primary tumour growth.  
 
 
Leucyl-cystinyl aminopeptidase (LNPEP, or hPLAP) is associated with the ‘signal 
transduction’ Gene Ontology Consortium Biological Process annotation that is over-
represented amongst the functional annotations assigned to the genes differentially 
expressed between the primary OMMs and lymph node metastases (Table 1). LNPEP 
encodes a protein that cleaves vasopressin, oxytocin and other peptide hormones 
(uniprot.org/uniprot/Q9UIQ6). It displays elevated expression in the lymph node 
metastases in this study, but its role in the development of human melanoma is 
unclear95, and further studies are needed to elucidate its potential role in tumour 
progression and metastatic dissemination. 
 
Conclusions: 
This study has demonstrated that canine OMM lymph node metastases are 
characterised by increased expression (relative to primary OMMs) of a set of genes 
involved in cell motility, cell interactions with the surrounding environment, and cell 
survival. On the basis of these results, all these gained/improved capabilities seem to 
be fundamental for the migration, and survival during migration, of neoplastic 
melanoma cells during dissemination through the lymphatic system and production of 
lymph nodal metastases. The potential key role of Rac1 and its upstream activators 
and downstream effectors in the modulation of critical elements of metastasis has been 
highlighted, as has previously been done in human medicine96. It is possible that 
melanoma cells are able to disseminate to distant sites due to re-acquisition of plastic 
and highly migratory behaviour characteristic of their embryonic precursors34. However, 
neoplastic melanocytes are possibly also able to apply mechanisms used by other cell 
 
lineages to succeed in the metastatic journey. Rac1 pathway activation could be one of 
these mechanisms as it is essential for lamellipodia formation. Indeed, lamellipodia 
formation is used by dendritic cells to interact with the endothelium, polarise and 
actively crawl toward the draining lymph node97.  
The role of Rac1 and its pathway in tumorigenesis, angiogenesis, invasion, and 
metastasis has been proven for several different human tumour types96, and it may 
have a similarly important role in canine OMM development and progression. Targeting 
Rac1 and its regulatory network would be beneficial for cancer treatment, but this has 
unfortunately proved to be difficult. Rac1 signalling is involved in many processes of 
normal cell physiology, like cellular plasticity, migration and invasion, cellular 
adhesions, cell proliferation, apoptosis, reactive oxygen species (ROS) production and 
inflammatory responses98. Therefore, targeting Rac1 in a clinical setting might have 
undesirable side effects. Investigation of both the downstream effectors and the 
upstream regulators of Rac1 could indicate the best unimodal/multimodal therapeutic 
approaches for canine OMMs. At this stage additional validation in different preclinical 
cancer models is needed to supplement the striking in vitro evidence of the benefits of 
targeting Rac199.   
 
Limitations of the study: 
The main limitation of this study is the relatively low number of OMM primary and 
lymph node metastasis biopsy pairs analysed. Fine needle aspiration (FNA) remains a 
mainstay diagnostic technique when evaluating for metastasis to regional lymph nodes 
in animals, including cancer staging in dogs with OMMs. FNA is less invasive 
compared to surgical excision and is frequently preferred to histological examination of 
the lymph node for this reason, despite the latter technique being considered to be the 
gold standard for identifying lymph node metastasis100. Therefore, only a few cases 
were found where both the primary canine OMM FFPE tissue and a matched lymph 
node metastasis was available.  
Furthermore, FFPE biopsies of primary and metastatic canine OMMs were used in the 
study. Degradation of RNA by formalin fixation is well known, and probably mainly 
affects accurate quantification of genes expressed at low levels. However, reliable data 




The differential expression of 12 genes involved in the Rac1 pathway identified by 
microarray mRNA profiling will be validated by quantitative Reverse transcription-
Polymerase Chain Reaction assay. Gene expression will be assayed in the 4 pairs of 
primary and lymph node biopsies utilised in the microarray study, and in a further 9 
pairs of primary canine OMMs and their lymph node metastasis.  
The comparative global gene expression profiling of primary OMMs and their lymph 
node metastases will be extended by RNA-sequencing of the additional 9 pairs of 
tumour biopsies. The objective will be to identify genes that show a consistent 
difference in expression between the primary and the metastatic tumours, and also 
genes which are recurrently affected by functionally-relevant exonic mutations that are 



















































Lymphatic invasion in canine oral melanoma: can the sensitivity of 










































Materials and methods: 
Ethics Statements: 
This study (Project number 33-2017) was approved by the Animal Health Trust (AHT) 
Ethics Committee. Informed, written consent was obtained from the owners of dogs 
whose primary oral melanomas were included in this study. A primary melanoma 
biopsy could be withdrawn from the study at any time. Patient treatment was 
unaffected by the study.  
 
Tumour Samples: 
Formalin fixed, paraffin embedded (FFPE) biopsies of canine primary OMMs from 21 
dogs (10 with a metastatic and 11 with a non-metastatic tumours) were retrieved from 
diagnostic histopathology archives [Pathology Department at the AHT (UK) and 
Department of Pathobiology at the University of Utrecht (Netherlands)]. The tissue 
biopsies were surgically excised from dogs (between 2012 and 2018) for treatment 
purposes. Eighteen representative FFPE blocks containing different areas of the 
primary neoplastic masses were selected for both the metastasising and non-
metastasising cases, totalling 36 tissue blocks. Metastatic and non-metastatic states 
were assessed by FNA and/or histopathology of the regional/draining lymph node and 
they were defined as the presence or absence of neoplastic melanoma cells in the 
lymph node, respectively.  
 
Evaluation of lymphatic invasion: 
Haematoxylin and eosin staining (H&E) and immunohistochemistry (IHC) for a 
lymphatic-specific marker, Prox-1 (AngioBio, Del Mar, CA, USA) (Appendix 6) were 
performed on each selected FFPE tissue block for evaluation of lymphatic invasion by 
melanoma cells. Confirmation of species cross-reactivity for Prox-1 antibody for FFPE 
canine tissue has been previously reported by Halsey et al23. We validated the antibody 
in our laboratory checking for presence of positive nuclear signal on efferent and 
afferent lymphatics in normal canine FFPE mesenteric lymph nodes and lacteals in 
normal canine small intestine. Negative controls, omitting the primary antibody, were 
included to assess non-specific background staining. 
 
The intratumoural (IT) and peritumoural (PT) presence of lymphatic invasion was 
blindly assessed by three pathologists (Brunetti B, Avallone G, Pellegrino V), using 
different optical microscopes (Leica DMLB100T, Optika B-350, Optika B-382PL 
respectively), but all with the same ocular lens field number (FN20).  
Evaluation of the stained sections (H&E and IHC) was performed following these 
criteria: 
• Avoid areas of necrosis. 
• Lymphatic vessels are defined as structures with a complete luminal profile 
lined by endothelial cells on H&E and structures lined by endothelial cells with 
complete nuclear positive staining on immunohistochemistry for Prox-1. 
• Lymphatic invasion is defined as the attachment of melanoma cells (single or in 
clusters) to the luminal side of endothelial cells or free in the vascular lumen. 
• Scoring is based on “lymphatic invasion” or “absence of lymphatic invasion”. 
Doubtful invasion has to be considered “absence of lymphatic invasion”. 
• The evaluation of lymphatic invasion has to be performed on an entire section 
containing the tumour and peritumoural area, scanning at 100X magnification 
and checking for suspect areas of invasion at 400X magnification on optical 
microscope. No evaluation of non-neoplastic tissue outside the PT area is 
required.  
• The PT area is defined as non-neoplastic tissue present within 10 microscopic 











The Kuder Richardson Coefficient of reliability (K-R 20) test was used to assess the 
degree of concordance between the three pathologists in determining the absence or 
presence of lymphatic invasion. The K-R 20 test value was interpreted as follow: 
 





>0.8 near complete agreement 
 
Concordance analysis was performed on “single slides” (all slides obtained from the 
selected OMMs) and “cases” (when more than one slide was available for the same 
tumour, they were grouped together and considered as a single case). 
Different analyses were performed based on: 
• Evaluation of only H&E-stained sections 
• Evaluation of only Prox-1 immunostained sections 
• A combination of the H&E and Prox-1 IHC evaluations 











Interobserver agreement on lymphatic invasion in canine primary OMMs: 
The degree of agreement between the three pathologists in determining the presence 
or absence of lymphatic invasion in primary OMM sections was calculated. Detection of 
lymphatic invasion in a cohort of 10 metastatic and 11 non-metastatic canine OMMs 
was performed on a total of 36 H&E stained sections (figure 8) and 36 Prox-1 IHC-
stained sections (figure 9). Lymphatic vessels were detected in IT and PT areas both 
































H&E IHC Prox-1 H&E IHC Prox-1 
P1 P2 P3 P1 P2 P3 P1 P2 P3 P1 P2 P3 
1 Yes 3 No No No No No No No Yes No No Yes No 
2 Yes 2 No No No No No No No Yes No No No No 
3 Yes 5 No Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes 
4 Yes 2 No No Yes No No No Yes No Yes No No Yes 
5 Yes 1 No No No No No No No No No No No No 
6 Yes 1 No No No No No No No No No No No No 
7 Yes 1 No No No No No No Yes No Yes No No No 
8 Yes 1 No No No No No No No No No No No No 
9 Yes 1 No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
10 Yes 1 No No No No No No No Yes Yes No No Yes 
11 No 4 Yes No No No Yes No Yes No No No No No 
12 No 2 No No Yes No No No No No No No No No 
13 No 3 No No No No No Yes No No Yes No Yes No 
14 No 2 No No No No No No No No No No No No 
15 No 1 No No No No No No No No No No No No 
16 No 1 No No No No No No No No No No No No 
17 No 1 No Yes Yes Yes No No No No No No No No 
18 No 1 No No No No No No No No No No No No 
19 No 1 No No No No No No No No No No No No 
20 No 1 No No No No No No No No No No No No 
21 No 1 Yes Yes Yes No Yes No No No No No No No 
 
Table 2: Presence (Yes) or absence (No) of lymphatic invasion reported by all three pathologists for each 









Figure 8: Melanoma cells in the lumen of a vascular structure (most likely a lymphatic vessel based on the 





Figure 9: Strong positive nuclear signal for Prox-1 in endothelial cells in some vessels (red arrows), with 












Based on H&E stained sections, the degree of agreement upon evaluation of “cases” 
was always higher (moderate to strong) than that achieved through evaluation of 
“single slides” (fair to moderate), independent of the area(s) selected (IT, PT, IT+PT). 
The highest degree of agreement (0.68/strong) was achieved in IT areas for “cases”. 
The lowest degree of agreement (0.35/fair) was achieved for “single slides” when 




Figure 10: The degree of agreement in regard to the identification of lymphatic invasion in H&E-stained 
primary OMM sections measured by the K-R 20 test. IT: intratumoural; PT: peritumoural; IT+PT: 



































Similar results were obtained by examination of IHC sections stained with Prox-1. 
Indeed, higher degree of agreement was achieved on evaluation of IHC-stained 
“cases” (fair to strong) compared to “single slides” (poor to fair). The highest degree of 
agreement (0.72/strong) was achieved in PT areas for “cases”. The lowest degree of 
agreement (0.17/poor) was achieved on “single slides” from IT areas. Detailed values 
are depicted in figure 11. 
 
Figure 11: The degree of agreement in regard to the identification of lymphatic invasion in Prox-1 IHC-
stained primary OMM sections measured by the K-R 20 test. IT: intratumoural; PT: peritumoural; IT+PT: 




































Finally, combining evaluation of lymphatic invasion from H&E and Prox-1 IHC-stained 
sections, the degree of agreement was strong for “cases”, and fair to moderate for 
“single slides”. The highest degree of agreement (0.76/strong) was achieved for 
“cases” in IT areas and the lowest (0.38/fair) for “single slides” in PT areas.  the K-R 
20 test values are depicted in figure 12. 
 
  
Figure 12: The degree of agreement in regard to the identification of lymphatic invasion in H&E and Prox-
1 IHC-stained measured by K-R 20 test. IT: intratumoural; PT: peritumoural; IT+PT: intratumoural + 
peritumoural areas.  
 
The highest degree of agreement between the three different pathologists was 
achieved with evaluation of H&E+IHC “cases”, even though there was no significant 
difference compared to the evaluation of only H&E “cases” (strong agreement in both 
evaluations for all areas, except for a moderate agreement on H&E in IT+PT areas). 
The trend of agreement based on “cases” matched the trend on “single slides”.  
 
Sensitivity and specificity of detection of lymphatic invasion in predicting lymph 
nodal metastasis: 
Sensitivity and specificity have been calculated on the category (lymphatic invasion 
present or absent) assigned most often by examination of H&E and Prox-1 IHC-stained 


























Agreement on H&E+IHC sections
 
of all sections available from an OMM better reflects the real daily diagnostic setting, 
we decided to include only “cases” and not “single slides” in this analysis. Table … 
shows detailed results.  
In this study, lymphatic invasion was detected in 12 “cases” in total with examination of 
H&E stained sections. Unexpectedly, using Prox-1 IHC, only 8 “cases” with lymphatic 
invasion were detected. Combined use of H&E and IHC did not increase detection of 
lymphatic invasion (12 “cases”), being all “cases” stained with Prox-1 detected with 
H&E stained sections.  
The sensitivity in predicting lymph nodal metastasis by evaluation of H&E or Prox-1 
IHC-stained IT areas was low, ranging from 13.3% to 46.7%. Higher sensitivities were 
obtained from the evaluation of PT and IT+PT areas.  
On the other hand, specificity was high, with consequent low numbers of false positives 




Figure 13: Sensitivity of predicting regional lymph node metastasis by lymphatic invasion assessed by 
H&E-staining, Prox-1 IHC, or the two combined. IT: intratumoural area; PT: peritumoural areas; IT+PT: 
























Figure 14: Specificity of predicting regional lymph node metastasis by lymphatic invasion assessed by 
H&E-staining, Prox-1 IHC, or the two combined. IT: intratumoural area; PT: peritumoural areas; IT+PT: 








































The presence of LVI in a primary tumour is generally considered an unfavourable 
prognostic factor for several human cancers14–17. In addition to LVI, either lymphatic 
vessel invasion or blood vessel invasion individually are reported to be prognostic15. 
The prognostic value of lymphatic invasion detected in H&E-stained sections from the 
primary site has also been demonstrated in dogs with oral and cutaneous melanocytic 
tumours18.  
The clinical relevance of enhanced detection of LVI by immunohistochemistry has been 
proven in human melanomas, with IHC-detected LVI more significantly associated with 
adverse clinicopathologic variables than LVI detected by routine histology14. IHC 
staining has also been shown to increase the sensitivity of lymphatic invasion detection 
by up to nine-fold compared to that achieved by H&E staining20. 
Therefore, this study set out to evaluate if the use of IHC for lymphatic vessels could 
also be applied in the veterinary field for increasing the detection of lymphatic invasion 
by neoplastic cells, specifically those derived from canine primary OMMs. 
The use of Prox-1 as a marker for lymphatic invasion was chosen due to the reported 
cross-reactivity of an antibody raised against the human Prox-1 protein in canine FFPE 
tissue and the better performance of the antibody in regard to signal strength and 
background staining, compared to other markers (see Introduction). 
Unexpectedly, in this study the use of Prox-1 IHC did not improve the detection of 
lymphatic invasion by neoplastic melanocytes in canine primary OMM sections beyond 
that achieved by H&E staining. Indeed, lymphatic invasion was detected in a larger 
number of primary OMMs by evaluation of H&E stained sections than by evaluation of 
Prox-1 IHC sections. These results contrast with those of several previous studies that 
have found that the use of IHC for specific lymphatic markers increased the detection 
of lymphatic invasion19,102. 
The lack of efficacy of Prox-1 IHC at detecting lymphatic invasion in primary OMMs in 
this study may be due to several factors. A positive IHC signal might have been 
“hidden” in the melanoma samples. Indeed, the chromogen (3’-diaminobenzidine/DAB) 
used produces brown ‘positive’ staining. However, the frequent presence in the 
tumours of melanin pigment (brown to black colour in sections from FFPE tissue) could 
have effectively decreased the sensitivity with which positive lymphatic vessels could 
 
be detected (low contrast between positive IHC signal and melanin pigment), even if a 
clear distinction between IHC signal and melanin in regard to sub-cellular localisation is 
possible as Prox-1 positive signal is present in the nucleus of endothelial cells and 
melanin is localised in the cytoplasm of melanomas cells. Another potential issue that 
would have resulted in a lower rate of lymphatic invasion detection is the difficult 
delineation of the cellular borders of endothelial cells in IHC-stained sections compared 
to those visualised in H&E-stained sections (as just said, Prox-1 IHC gives only a 
positive nuclear signal). Consequently, it was sometimes challenging to determine if 
lymphatic vessels were collapsed due to compression by melanoma cells, or if the 
vascular lumen was completely filled with neoplastic cells, despite the detection of 
positive nuclei of endothelial cells in the area. Future projects could try to use other 
lymphatic-specific markers (e.g. LYVE-1, which gives a cytoplastic positive signal) and 
an alternative chromogen (e.g. 3-Amino-9-Ethylcarbazole/AEC, which is a red 
chromogen) to try to solve these potential issues and improve the sensitivity of the 
assay.  
Interestingly, the study showed that the sensitivity of detecting lymphatic invasion could 
be increased by evaluating peritumoural (PT) areas, instead of intratumoural (IT) areas 
in canine primary OMMs. In human medicine there has been a long debate regarding 
the biological and clinical roles of intratumoural lymphatic vessels. Some studies have 
shown that a relatively high incidence of IT LVI correlates with adverse clinical outcome 
and with sentinel lymph nodal metastasis, whereas others have reported that LVI is 
more common, or is only detected in the PT area14. Moreover, functional studies of 
xenograft mice have suggested that IT lymphatic vessels are not functional and that the 
ones at the tumour margins are solely responsible for the metastatic dissemination103. 
Therefore, one can hypothesise that canine OMMs may preferentially use PT lymphatic 
vessels to disseminate to distant organs. 
Assessment of the correlation between presence of lymphatic invasion in the primary 
tumour and lymph nodal metastasis was performed. Our results showed that evaluation 
of lymphatic invasion in canine primary OMMs seems to results in potential high 
numbers of false negatives (low sensitivity) and low numbers of false positives (high 
specificity) in predicting lymph node metastasis.   
Thinking about the strong functional and anatomical correlation between the lymphatic 
vessels and the regional/draining lymph nodes, one would assume that the presence of 
lymphatic invasion in the primary site always/frequently matches lymph nodal 
 
metastasis, or at least that lymphatic invasion in the primary site would occur more 
often than lymph nodal metastasis because not all neoplastic cells entering the 
lymphatic system are able to reach the lymph node. However, this assumption has 
been proven to be wrong as the reported incidence of LVI is disproportionately low 
compared to the incidence of sentinel lymph node positivity on routine histologic 
evaluation, for example in human cutaneous melanomas19. Similar results have also 
been reported from another study on human melanomas, where 75% of primary 
tumours with lymphatic invasion had metastatic lymph nodal metastasis and 31% of 
primary tumours without lymphatic invasion had metastatic lymph nodal metastasis19. 
The presence of lymphovascular invasion also showed a weak correlation with the 
occurrence of lymph nodal metastasis in human breast cancer16.  
Although lymphatic invasion is an early event in the metastatic process, it seems that it 
is a better predictor of the ultimate outcome of the disease rather than of a more 
immediate event such as sentinel/regional lymph node metastasis14. For the same 
reason, we can hypothesise that the spreading of melanoma cells from the primary site 
to the lymph node possibly took place early in the development of the tumour and 
therefore there is lower incidence of lymphatic invasion in the primary site at the time of 
excision.  
However, we have to bear in mind that assessment of LVI is variable between 
pathologists, depending on several factors. Only fair agreement among six pathologists 
in the evaluation of LVI in human colorectal cancer has been reported by Harris et al104. 
Rakha et al have shown that a high level of consistency of reporting LVI is possible in 
human breast cancer, however only with high numbers of involved lymphovascular 
spaces in the examined sections105. Beggan et al showed that variation of interobserver 
agreement in the diagnosis of LVI in human squamous cell carcinoma of the floor of the 
mouth can be substantial106. Interestingly, they pointed out that interpretative variation 
seems to be the main factor contributing to discrepant diagnoses. Our results can 
support the hypothesis that the same is true for the agreement in detecting lymphatic 
invasion in canine primary OMMs. Indeed, the agreement between our group of three 
pathologists was quite variable, despite we have tried to reduce presence of other 
factors potentially influencing observers’ concordance. For example, all three 
pathologists examined the same sections (H&E and Prox-1 IHC-stained sections), 
therefore not incurring in the possible variation of the tissue in different levels of each 
FFPE tissue block. We have also defined the specific features of “lymphatic invasion” 
 
for our study before starting the examination (see Materials and methods), limiting the 
variability in the criteria used to recognize and define lymphatic invasion by each 
pathologist.   
Therefore, future studies should aim to increase both the detection of lymphatic 
invasion and the agreement between pathologists to obtain more reliable data on the 
clinical and biological significance of lymphatic invasion in cancer. 
 
Limitations of the study: 
The main limitation of this study was the relatively low numbers of metastatic and non-
metastatic OMMs evaluated. Due to high frequency of nodal metastasis at 
presentation, identification of non-metastatic cases can be challenging, and 
representative and comparable cohorts of both metastatic and non-metastatic OMMs 
are required to obtain reliable results. Therefore, in a future study to number of cases 
would be expanded, and follow-up data on the occurrence of distant metastases 
potentially availed to try to test the hypothesis of the prognostic significance of 
lymphatic invasion, and evaluate the potential important role of peritumoural lymphatics 
in tumour metastasis. As previously discussed, adjustment of the IHC protocol may 
increase the detection of lymphatic vessels, and the reliability of other IHC markers for 
lymphatic vessel detection in canine OMMs could be investigated. 
 
Future work: 
In collaboration with Dr. McConnel, Research Associate from Dermatological Sciences, 
Institute of Cellular Medicine, Newcastle University, we are trying to investigate the 
potential use of IHC markers as prognostic factors in canine melanomas (oral and 
cutaneous). In particular, AMBRA1 (Autophagy And Beclin 1 Regulator 1) has been 
already shown to be predictive in term of prognosis for early stage human melanomas 
(Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the 
prognostication and stratification of the American Joint Committee on Cancer stage I 
melanomas. Ellis R et al. Br J Dermatol. 2019 May 6. doi: 10.1111/bjd.18086. [Epub 
ahead of print]). We already tried to investigate the expression of AMBRA1 in canine 
tissues (skin and oral mucosa), with promising results. Our aim for the next few months 
is to set up a scoring system for the evaluation of AMBRA1 in canine FFPE OMM 
samples and expand the cohort of cutaneous melanoma in collaboration with Dr 
 

















































Scientific activity carried out during the PhD: 
My scientific activity has taken place mainly at the Department of Pathology and at the 
Department of Molecular Oncology of the Animal Health Trust (United Kingdom), under 
close supervision of Dr. Mike Starkey (Head of Molecular Oncology) and distant 
supervision of Prof. Brunetti Barbara from the Department of Veterinary Medical 
Science of Alma Mater Studiorum-Bologna University. The PhD project focused on 
canine oral malignant melanomas, in particular on several genomic and 
immunohistochemical features which could be used in the future for prognostic 
purposes. 
During these three years, I had the opportunity to increase my knowledge on different 
genomic approaches to investigate variation in gene expression between canine 
primary oral mucosal melanomas and their matched lymph nodal metastases. I have 
been involved in the study plan since the beginning, trying to adjust the project 
according to the time, funding and material available. I have been in the lab to do 
myself several experiments, under the supervision of Dr. Starkey. Internal (Animal 
Health Trust as Collaborator) and external (Petplan Charitable Trust-Pump Priming 
Grant as Primary Investigator) funding have been obtained to support the project. 
Currently, I am waiting for the decision upon application for funding to the American 
Kennel Club Canine Health Foundation-Acorn Grant as Co-Primary Investigator 
(together with Dr. Starkey) to be able to perform RNA-sequence analysis, quantitative 
RT-PCR and Sanger DNA sequencing in the collected canine oral malignant 
melanoma samples. 
Internal (Animal Health Trust as Principal Investigator) funds have been awarded to 
support the Prox-1 immunohistochemical study on canine primary oral melanomas. 
During my PhD, I have been working at the Animal Health Trust as Anatomic 
pathologist and for 6 months as Acting Head of Anatomic pathology, being responsible 
for the biopsy and necropsy services. I have been training with rounds and seminars on 
anatomic pathology Interns and Residents in different disciplines during these years 
and I have been the supervisor of an Intern in Anatomic pathology for 8 months. I have 




Publications during the PhD: 
• Inter- and Intraobserver Agreement of Canine and Feline Nervous System 
Tumors. Belluco S, Avallone G, Di Palma S, Rasotto R, Oevermann A. 
Veterinary Pathology. 2019 May;5(3):342-349. 
• Identification of molecular genetic contributants to canine cutaneous mast cell 
tumour metastasis by global gene expression analysis. Bowlt Blacklock 
K, Birand Z, Biasoli D, Fineberg E, Murphy S, Flack D, Bass J, Di Palma 
S, Blackwood L, McKay J, Whitbread T, Fox R, Eve T, Beaver S, Starkey M. 
PLoS One. 2018 Dec 19;13(12):e0208026. 
• Meningeal carcinomatosis secondary to a suspected pulmonary carcinoma in a 
cat and comparison with human literature. Crespo V, Ortega M, Stabile F, Di 
Palma S, Fernandez Y. Veterinary Record Case Reports. 2018; 6(4). 
• Recurrent cerebrovascular accidents caused by intravascular lymphoma in a 
dog. Sanchez L, Beckmann K, Dominguez E, Di Palma S, Shea A. Veterinary 
Record Case Reports. 2018;6(3).  
• Spontaneous gall bladder infarction in a dog with a congenital extrahepatic 
portosystemic shunt. Olivares G, Fernandez Y, Di Palma S, Murgia D. 
Veterinary Record Case Reports. 2018;6(1). 
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• Lymphatic invasion in canine oral melanoma: can the sensitivity of detection be 
increased by Prox-1 immunohistochemistry? Pellegrino V, Avallone G, Brunetti 












































RNA extraction using the RecoverAll Total Nucleic Acid Isolation Kit: 
1. Transfer 3 tissue cores extracted from the highlighted areas of the FFPE block 
using a Miltex Biopsy punch with plunger into a Nuclease-free 2ml Eppendorf 
tube. 
2. Add 1.8ml of Histoclear to submerge the cores. Incubate at 37°C for 1 hour on a 
rotary mixer. 
3. Centrifuge at 13,000 rpm for 10 minutes at room temperature to pellet the 
tissue. Carefully remove the Histoclear. 
4. Add 1ml of 100% ethanol and mix by vortexing. Centrifuge at 13,000 rpm for 2 
minutes at room temperature to pellet the tissue. Carefully remove the ethanol-
Histoclear.  
5. Add 1ml of 100% ethanol and mix by vortexing. Centrifuge at 13,000 rpm for 2 
minutes at room temperature to pellet the tissue. Carefully remove as much the 
ethanol-Histoclear as possible.  
6. Add 1ml of 10% Phosphate-buffered saline/PBS (pH 7.2) and mix by vortexing. 
Centrifuge at 13,000 rpm for 2 minutes at room temperature to pellet the tissue. 
Carefully remove the PBS-Histoclear. 
7. Add 1ml of 10% PBS (pH 7.2) and mix by vortexing. Centrifuge at 13,000 rpm 
for 5 minutes at room temperature to pellet the tissue. Carefully remove the 
PBS-Histoclear. 
8. Allow the tissue pellet to air dry for 1 hour. 
9. Add 400µl of Digestion Buffer and 8µl of Protease. 
10. Swirl gently to mix and to immerse the tissue. Briefly centrifuge to bring the 
tissue down into the solution. 
11. Incubate in a waterbath at 50°C for 3 hours. 
12. Transfer a 200µl aliquot into a 2ml Nuclease-free Eppendorf tube.  
13. Incubate the 200µl aliquot at 80°C for 15 minutes. 
14. Add 240µl of Isolation Additive and mix by vortexing. Add 550µl of 100% 
ethanol and mix by pipetting. 
15. Centrifuge at 10,200 rpm for 10 seconds at room temperature. 
16. Pipette 700µl of the ~994µl sample/ethanol mixture onto a Filter Cartridge 
placed inside a Collection Tube. 
 
17. Centrifuge at 10,200 rpm for 60 seconds to pass the mixture through the filter. 
Discard the flow-through, and re-insert the Filter Cartridge in the same 
Collection Tube. 
18. Repeat steps 16. and 17. once more until all of the ~994µl sample/ethanol 
mixture has passed through the filter. Discard the flow-through on each 
occasion. 
19. Add 700µl of Wash 1 (to which ethanol was previously added) to the Filter 
Cartridge. Centrifuge at 10,200 rpm for 30 seconds to pass the mixture through 
the filter. Discard the flow-through, and re-insert the Filter Cartridge in the same 
Collection Tube. 
20. Add 500µl of Wash 2/3 (to which ethanol was previously added) to the Filter 
Cartridge. Centrifuge at 10,200 rpm for 30 seconds to pass the mixture through 
the filter. Discard the flow-through, and re-insert the Filter Cartridge in the same 
Collection Tube. Centrifuge at 10,200 rpm for 30 seconds to remove residual 
fluid from the filter. 
21. On ice, combine 50µl of Nuclease-free water, 6µl of 10 x DNase Buffer and 4µl 
of DNase. Carefully add the 60µl of DNase mix to the centre of the Filter 
Cartridge and incubate at 37°C for 30 minutes. 
22. Add 500µl of Wash 2/3 (to which ethanol was previously added) to the Filter 
Cartridge. Centrifuge at 10,200 rpm for 30 seconds to pass the mixture through 
the filter. Discard the flow-through, and re-insert the Filter Cartridge in the same 
Collection Tube.  
23. Repeat step 22. with a second 500µl of Wash 2/3, and re-insert the Filter 
Cartridge in the same Collection Tube. Centrifuge at 10,200 rpm for 1 minute to 
remove residual fluid from the filter. 
24. Transfer the Filter Cartridge to a fresh Collection Tube, and carefully apply 30µl 
of Nuclease-free water to the centre of the filter. Incubate at room temperature 
for 1 minute. Centrifuge at 13,000 rpm for 1 minute to elute RNA. 
25. Repeat step 24 with a second 30µl of Nuclease-free water, using the same 
Collection Tube. 






RNA samples purification by spin column filtration: 
1. Zymo-Spin IV-HRC Columns need to be prepared prior to use by: 
1.1. Snapping off the base 
1.2. Removing the cap 
1.3. Inserting into a Collection Tube 
1.4. Spinning in a microcentrifuge at 8,000 x g for 3 minutes 
2. Transfer 55-58µl RNA to a prepared Zymo-Spin IV-HRC in a clean 1.5ml 
microcentrifuge tube. 

















Measurement of total RNA concentration using the NanoDrop spectrophotometer: 
1. Pipette 2µl of total RNA for each sample onto the lower measurement pedestal. 
2. Close the sampling arm and initiate a spectral measurement using the 
operating software on the PC. 
3. When the measurement is complete, open the sampling arm and wipe the 
sample from both the upper and lower pedestal using a soft laboratory wipe. 
4. Record the value obtained from the measurement. 
5. Pipette 2µl of water aliquots to clean the measurements surfaces and then wipe 
the surfaces with a soft laboratory wipe. 
















Measurement of total RNA concentration using the Quant-iT RiboGreen assay: 
1. Prepare 50ml of 10mM Tris-HCl (pH 7.5), 1mM EDTA by diluting 2.5ml of 
200mM Tris-HCl, 20 mM EDTA in 47.5ml of Nuclease-free water. 
2. Dilute 1µl of each RNA sample (previously quantified by UV spectrophotometry) 
in a volume of 10mM Tris-HCl, 1mM EDTA that yielded a concentration of 
900ng/ml. 
3. Prepare 5x “high range E. coli 16S and 23S rRNA standars” to obtain final RNA 
concentration in assay of 1 µg/ml, 500 ng/ml, 100 ng/ml, 20 ng/ml and 0 ng/ml. 
4. Prepare 33µl of 1x RiboGreen reagent in 10mM Tris-HCl, 1mM EDTA for every 
RNA sample by diluting stock RiboGreen reagent 200-fold in 10mM Tris-HCl, 
1mM EDTA. 
5. Combine 10µl of RNA and 10µl of 1x RiboGreen reagent in each of 3 x 0.2ml 
PCR tubes. For each of the triplicate 0 ng/ml rRNA standard assay, add 10µl of 
10mM Tris-HCl, 1mM EDTA to 10µl of 1x RiboGreen reagent. Perform 3x 
assays for each RNA sample and rRNA standard. Seal the 96-well plate with a 
MicroAmp Otpical Adhesive. Store in the dark for 2-5 minutes. 
6. Centrifuge the PCR plate at 1000 rpm for 1 minute. 
7. Measure the fluorescence of each sample using the ABI StepOnePlus PCR 
machine (5 cycles of 20°C for 10 seconds). 
8. For each PCR plate well that contains a RNA sample (including the 0ng/ml 
rRNA standard), calculate the median of RiboGreen fluorescence signal 
intensity from the value obtained for each well in each of the 5 cycles.   
9. For each RNA sample, calculate the median RiboGreen fluorescence signal 








Preparation of biotin-labelled single-stranded-cDNA for hybridisation to a Canine Gene 
1.1 ST Array Strip 
1. Tumour RNA sample preparation  
1.1. Adjust the RNA concentration of each sample to obtain 3µl of RNA solution 
containing approximately 29ng/µl of RNA. 
2. First strand cDNA synthesis and excess primer removal 
2.1. On ice, combine 3µl (≥2ng) of each RNA sample with 2µl of Poly-A Control 
RNA Dilution 4 in a RNase-free 1.5ml Eppendorf tube. 
2.2. Add 5µl of First-Strand Master Mix to each. Mix thoroughly by gentle vortexing. 
Briefly centrifuge and place on ice. Transfer each into a PCR microtitre plate 
well. Briefly centrifuge and place on ice. 
2.3. In a PCR machine (Heated lid set at 42°C), incubate at 25°C for 5 min, 42°C 
for 60 min and 4°C for 5 min. Briefly centrifuge. 
2.4. Place the microtite plate on ice, and after 2 min, add 2µl of WT Pico Cleanup 
Reagent to each First-Strand cDNA Synthesis Mix. Mix gently by pipetting and 
ensure that all the liquid has been expelled from the pipette tip. Briefly 
centrifuge and place back on ice. 
2.5. In a PCR machine (Heated lid set at 105°C), incubate at 37°C for 30 min, 80°C 
for 10 min, and 4°C for 5 min. Briefly centrifuge and place the microtitre plate 
on ice. 
2.6. Start a 15°C, 'forever' run on the PCR machine block that will be used for the 
'3' Adaptor synthesis' reactions. 
3. 3` Adaptors synthesis 
3.1. On ice, add 8µl of 3' Adaptor Master Mix to each 12µl first strand cDNA 
sample. Mix gently by pipetting up and down. Briefly centrifuge and place back 
on ice.  
3.2. In a PCR machine (Heated lid turned off), incubate at 15°C for 15 min, 35°C for 
15 min, 70°C for 10 min and 4°C for 5 min. Briefly centrifuge (4,000 rpm, 1 min) 
and place the microtitre plate on ice. 
4. Pre-In Vitro Transcription (IVT) ds-cDNA PCR amplification 
4.1. On ice, add 30µl of Pre-IVT Amplification Master Mix to each 20µl adaptored 
first strand cDNA sample. Mix gently by pipetting up and down. Briefly 
centrifuge and place back on ice. 
 
4.2. In a PCR machine (Heated lid set at 105°C), incubate at 95°C for 2 min, 
followed by 12 cycles of (94°C for 30s, 70°C for 5 min), and 4°C for 5 min. 
Briefly centrifuge and place the microtitre plate on ice. 
5. In Vitro Transcription 
5.1. Incubate the microtitre plate containing the ds-cDNA samples at room 
temperature for 5 min. 
5.2. To each 50µl cDNA sample, add 30µl of IVT Master Mix. Mix gently by 
pipetting up and down. Centrifuge briefly. 
5.3. In a PCR machine (Heated lid set at 40 or 50°C), incubate at 40°C for 16h, and 
4°C 'forever'. Briefly centrifuge 
6. Purification of cRNA 
6.1. Shake/vortex the Purification beads to resuspend the beads. Dispense 154µl of 
Purification beads per cRNA sample into an RNAse-free 2ml Eppendorf tube. 
Store at room temperature. 
6.2. Place 2 x 1ml tubes of Nuclease-free water in the 65°C Hybridisation Oven. 
6.3. Prepare 7ml of 80% (v/v) ethanol. 
6.4. For each sense RNA sample, aliquot 140µl of purification beads into 1 well of a 
round bottom 96-well microtitre plate. Store at room temperature. 
6.5. Add a 80µl cRNA sample to each microtitre plate well. Mix gently by pipetting 
up and down. 
6.6. Incubate at room temperature (20-25°C) for 10 min. 
6.7. Place the microtitre plate on a magnetic stand for 10 min to separate the beads 
from the solution. 
6.8. Slowly remove (and discard) the ~220µl solution, taking care not to disturb the 
purification beads. 
6.9. Whilst on the magnetic stand, add 200µl of 80% (v/v) ethanol to each well. 
Incubate at room temperature for 30s. 
6.10. Slowly remove the 80% (v/v) ethanol taking care not to disturb the 
purification beads. 
6.11. Repeat steps 9. and 10. twice more. Completely remove the 80% (v/v) 
ethanol. 
6.12. Allow the beads to air-dry on the magnetic stand for at least 5 min until 
no liquid is visible and yet the bead pellets appear shiny. 
6.13. Remove the microtitre plate from the magnetic stand, and add 27µl of 
the 65°C Nuclease-free water to each well. 
 
6.14. Once water has been added to all the wells, incubate at room 
temperature for 3 min, pipetting the beads up and down to resuspend. 
6.15. Place the microtitre plate on the magnetic stand for 5 min to separate 
the beads from the solution. 
6.16. Carefully aspirate each cRNA sample into a RNase-free 1.5ml 
Eppendorf tube (placed on ice). Record the volume recovered. 
6.17. Measure the concentration and 'purity' of a 1µl aliquot (diluted with 1µl of 
Nuclease-free water) of each cRNA sample using the NanoDrop. 
6.18. Store at -20°C overnight OR at -70°C long-term. 
7. Single-stranded cDNA synthesis 
7.1. On ice, dispense each 24µl (=20µg) cRNA sample into a RNase-free 1.5ml 
Eppendorf tube. 
7.2. Add 16µl of 2nd-Cycle ss-cDNA Master Mix to each. Mix gently by tube flicking. 
Briefly centrifuge and place on ice. Transfer each into a PCR microtitre plate 
well. 
7.3. In a PCR machine (Heated lid set at 70°C), incubate at 25°C for 10 min, 42°C 
for 90 min, 70°C for 10 min, and 4°C 'forever'. Briefly centrifuge. 
8. RNA removal 
8.1. On ice, add 4µl of RNase H to each 40µl 2nd-Cycle ss-cDNA sample. Mix 
gently by pipetting up and down twice. Centrifuge briefly. Place back on ice. 
8.2. In a PCR machine (Heated lid set at 105°C), incubate at 37°C for 45 min, 95°C 
for 5 min, and 4°C 'forever'. Briefly centrifuge and place on ice. 
8.3. Add 11µl of Nuclease-free water to each 44µl ss-cDNA sample. Mix gently by 
pipetting up and down twice. Centrifuge briefly. Place back on ice. 
9. Purification of ss-cDNA 
9.1. Shake/vortex the Purification beads to resuspend the beads. Dispense 110µl of 
Purification beads per ss-cDNA sample into an RNAse-free 2ml Eppendorf 
tube. Store at room temperature. 
9.2. Place 3 x 1ml tubes of Nuclease-free water in the 65°C Hybridisation Oven. 
9.3. Prepare 7ml of 80% (v/v) ethanol. 
9.4. For each ss-cDNA sample, aliquot 100µl of purification beads into 1 well of a 
round bottom 96-well microtitre plate. Store at room temperature. 
9.5. Add a 55µl ss-cDNA sample to each microtitre plate well. Mix gently by 
pipetting up and down. 
 
9.6. Add 150µl of 100% (v/v) ethanol to each sample. Mix gently by pipetting up 
and down. 
9.7. Incubate at room temperature (20-25°C) for 20 min. 
9.8. Place the microtitre plate on a magnetic stand for 10 min to separate the beads 
from the solution. 
9.9. Slowly remove (and discard) the ~305µl solution, taking care not to disturb the 
purification beads. 
9.10. Whilst on the magnetic stand, add 200µl of 80% (v/v) ethanol to each 
well. Incubate at room temperature for 30s. 
9.11. Slowly remove the 80% (v/v) ethanol taking care not to disturb the 
purification beads. 
9.12. Repeat steps 10. and 11. twice more. Completely remove the 80% (v/v) 
ethanol. 
9.13. Allow the beads to air-dry on the magnetic stand for at least 5 min until 
no liquid is visible and yet the bead pellets appear shiny. 
9.14. Remove the microtitre plate from the magnetic stand, and add 30µl of 
the 65°C Nuclease-free water to each well. 
9.15. Once water has been added to all the wells, incubate at room 
temperature for 3 min, pipetting the beads up and down to resuspend. 
9.16. Place the microtitre plate on the magnetic stand for 5 min to separate 
the beads from the solution. 
9.17. Carefully aspirate each ss-cDNA sample into a RNase-free 1.5ml 
Eppendorf tube (placed on ice). Record the volume recovered. 
9.18. Measure the concentration and 'purity' of a 1µl aliquot (diluted with 1µl of 
Nuclease-free water) of each ss-cDNA sample using the NanoDrop. 
9.19. Store at -20°C overnight OR at -70°C long-term. 
10. Fragmentation and labelling of single-stranded cDNA 
10.1. On ice, dispense each 46µl Single-Stranded cDNA sample into a 
RNase-free 1.5ml Eppendorf tube. 
10.2. Add 14µl of Fragmentation and Labelling Master Mix to each. Mix 
thoroughly by gentle vortexing. Briefly centrifuge and place on ice. Transfer 
each into a PCR microtitre plate well. 
10.3. In a PCR machine (Heated lid set at 93°C), incubate at 37°C for 60 min, 
93°C for 2 min, and 4°C `forever`. Briefly centrifuge. 
 
10.4. Transfer each 60µl fragmented and labelled Single-Stranded cDNA 
sample to a RNase-free 1.5ml Eppendorf tube. 
11. Hybridization cocktail preparation 
11.1. For each ss-cDNA sample, at room temperature, in a RNase-free 1.5ml 
Eppendorf tube combine: 
11.1.1. Hybridisation Master Mix (49µl per sample) 
11.1.2. Fragmented and labelled Single-Stranded cDNA (41µl per sample) 















































Immunohistochemistry for PROX-1: 
1. A 3-µm thick section is obtained from each case and mounted on a pre-cleaned  
X-tra Adhesive slide (Leica Biosystems). 
2. Slides are left in the oven overnight at 45-50°C. 
3. Place overnight dried slides into Dako PT Link for antigen retrieval (EnVision FLEX 
Target Retrieval Solution, Low pH/ citrate buffer pH 6.1). 
3.1. Fill PT Link with sufficient quantity of working solution to cover the tissue 
sections. 
3.2. Set PT link to pre-heat the solution at 65°C 
3.3. Immerse the tissue sections into the pre-heated Target Retrieval Solution and 
incubate for 30 minutes at 97°C. 
3.4. Leave the sections to cool in PT Link to 65°C. 
3.5. Remove the slides from the PT Link and dip them into a jar with diluted Dako 
Wash Buffer at room temperature. 
3.6. Leave slides for 5 minutes. 
4. Put slides in Dako Autostainer Plus Link to perform immunohistochemistry run with 
the following program. 
4.1. Dako Wash Buffer: 0 minutes 
4.2. Envision Flex Peroxidase Block Reagent (Dako): 5 minutes 
4.3. Dako Wash Buffer: 0 minutes 
4.4. Prox-1 antibody (dilution 1:500): 20 minutes 
4.5. Dako EnVision+ System – HRP (Dako): 30 minutes 
4.6. Dako Wash Buffer: 5 minutes 
4.7. DAB + Substrate Chromogen System (Dako): 10 minutes 
4.8. Dako Wash Buffer: 0 minutes 
4.9. Haematoxylin: 5 minutes 
4.10. Rinse deionized Water: 0 minutes 
4.11. Dako Wash Buffer: 5 minutes 
4.12. Rinse deionized Water: 0 minutes  
5. Dehydrate tissue sections. 
5.1. 3 changes of 95% ethanol for 1-2 minutes each 
5.2. 2 changes of 100% ethanol for 1-2 minutes each 
5.3. 3 changes of Xylene for 1 minute each 
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